证券代码：603718 证券简称：海利生物 公告编号：2024－016 1、第四届董事会第二十二次会议决议； 2、第四届董事会审计委员会 2024 年度第一次会议决议。 上海海利生物技术股份有限公司 第四届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 二、董事会会议审议情况 1、审议通过了《关于 2023 年年度股东大会取消部分议案的议案》 鉴于公司拟聘任的会计师事务所大华会计师事务所（特殊普通合伙）被暂停 从事证券服务业务 6 个月，经与其协商，基于谨慎性原则，公司决定取消 2023 年年度股东大会中第 8 项提案，即《关于续聘会计师事务所的议案》。公司聘请 2024 年度审计机构事项将另行召开董事会并提交股东大会审议。 已经公司第四届董事会审计委员会 2024 年度第一次会议审议通过。具体内 容详见公司同日在上海证券交易所披露的《上海海利生物技术股份有限公司关于 2023 年年度股东大会取消部分议案的公告》。 表决结果：7 票同意、0 票反对、0 票弃权。 三、备查文件 一、董事会会议 ...

Financial Performance - The company achieved a net profit attributable to the parent company of RMB 62,870,202.71 for the fiscal year 2023, with distributable profits for shareholders amounting to RMB 426,801,334.54[6]. - In 2023, the company's operating revenue decreased by 19.76% to CNY 240,722,981.59 compared to CNY 299,991,674.85 in 2022[21]. - The net profit attributable to shareholders fell by 48.30% to CNY 62,870,202.71 from CNY 121,607,849.73 in the previous year[21]. - The net cash flow from operating activities dropped significantly by 102.86%, resulting in a negative cash flow of CNY -8,367,280.38[21]. - The basic earnings per share decreased by 47.37% to CNY 0.10, down from CNY 0.19 in 2022[22]. - The company's total assets increased by 9.48% to CNY 1,657,749,783.34 compared to CNY 1,514,252,528.46 at the end of 2022[21]. - The weighted average return on equity decreased by 6.01 percentage points to 5.32% from 11.33% in the previous year[22]. - The gross profit margin for the main business was 50.24%, down 8.70% year-on-year[53]. - Revenue from veterinary biological products was CNY 123.30 million, a decline of 35.61% year-on-year[53]. - The gross margin for veterinary biological products was 39.73%, down by 13.77% year-on-year[78]. Profit Distribution - A cash dividend of RMB 0.287 per 10 shares (including tax) is proposed for the profit distribution plan for the fiscal year 2023[6]. - The cash dividend ratio for the year is 30.03%, which represents the total cash dividend amount as a percentage of the net profit attributable to shareholders[155]. - The company will distribute at least 30% of the distributable profits as cash dividends if there are no major investment plans or significant cash expenditures[149]. - The board of directors will propose the profit distribution plan annually based on the company's profitability and cash flow situation, which will then be submitted for shareholder approval[150]. - The company has confirmed that the cash dividend policy complies with its articles of association and shareholder resolutions[153]. Risk Management and Compliance - The company emphasizes the importance of risk management and has detailed various operational risks and corresponding mitigation strategies in the report[7]. - The report outlines the company's commitment to compliance with regulatory standards and practices in its operations[7]. - The company has not faced any violations in decision-making procedures regarding external guarantees[7]. - The company confirms that there are no non-operational fund occupations by controlling shareholders or related parties[7]. - The company is committed to enhancing internal management and compliance to mitigate operational risks and improve corporate governance[104]. Corporate Governance - The board of directors and supervisory board members have all attended the board meeting, ensuring governance transparency[6]. - The company has established a modern corporate governance structure, ensuring equal rights for all shareholders, particularly minority shareholders[112]. - The board of directors and supervisory board comply with legal requirements and actively participate in training to fulfill their responsibilities[113]. - The company has implemented a strict information disclosure management system to ensure timely and accurate communication with shareholders[114]. - The company has revised its internal control systems and governance documents to comply with new regulations regarding independent directors[115]. Research and Development - The company has increased its R&D investment and established a research center in collaboration with Northwest A&F University, enhancing its innovation capabilities[32]. - The company aims to launch at least five new products annually, ensuring continuous innovation and development[46]. - The company has invested in expanding its R&D facilities by over 1,300 square meters to enhance the development of key raw materials[79]. - The company is focusing on R&D strategies that combine market orientation with technological upgrades to enhance product offerings[79]. - The company’s R&D investment in recombinant antibodies was 690.84 million RMB, showing an increase of 80.64% compared to the previous year[85]. Market and Business Strategy - The company has restructured its business focus towards the more profitable "human health" sector, particularly through its subsidiary, Shanghai Jiemen Biotechnology Co., which specializes in IVD products[39]. - The company aims to strengthen its competitive position in the market by focusing on high-quality products and innovative R&D capabilities[36]. - The company is considering strategic acquisitions to bolster its market position, with potential targets identified in the I sector[199]. - The company is actively seeking domestic suppliers to reduce import dependency and is increasing investment in raw material R&D to diversify product offerings[110]. - The company plans to implement a "full staff marketing" strategy in 2024, ensuring existing government procurement markets are maintained while expanding into new regions and reducing service fees[102]. Environmental and Social Responsibility - The company invested 18.19 million yuan in environmental protection during the reporting period[168]. - The company has established an environmental management system in accordance with GB/T24001—2004/ISO14001:2004, with no environmental pollution incidents reported in 2023[183]. - The company actively participated in social responsibility initiatives, including donating RMB 37,500 worth of disaster relief materials during the 2023 flood in Baoding, Hebei[187]. - The company has been recognized as a "Demonstration Point for Party Branch Construction" by the district committee, enhancing its operational capabilities[182]. - The company is committed to maintaining a harmonious relationship with society, the environment, and its stakeholders[186]. Employee Management - The total number of employees at the parent company and major subsidiaries is 295, with 125 in production, 39 in sales, and 86 in technical roles[142]. - The company emphasizes a broad salary policy based on job value and individual capability, implementing performance assessments to motivate employees[144]. - The company organized various training programs for management and staff, enhancing quality awareness and professional skills[145]. - The company has a comprehensive employee welfare system and actively conducts various training and team-building activities[178]. - The employee stock ownership plan is designed to align employee interests with company performance, enhancing retention and motivation[200].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 70,304,397.74, a decrease of 1.31% compared to the same period last year[3]. - The net profit attributable to shareholders was CNY -3,719,366.81, representing a decline of 126.13% year-over-year[3]. - Basic earnings per share were CNY -0.01, a decrease of 126.13% year-over-year[3]. - The company's gross profit margin decreased, with a gross profit of ¥30,750,596.80 in Q1 2024, down from ¥42,936,674.43 in Q1 2023[21]. - Net profit for Q1 2024 was a loss of ¥4,361,103.22, compared to a profit of ¥13,593,233.44 in Q1 2023[21]. - The company reported a comprehensive loss of ¥12,631,759.31 for Q1 2024, compared to a comprehensive income of ¥16,633,993.44 in Q1 2023[22]. Cash Flow - The net cash flow from operating activities was CNY -1,229,734.74, down 96.54% compared to the previous year[3]. - Cash flow from operating activities was ¥51,603,053.97, down from ¥62,861,217.44 in Q1 2023, indicating a decline in cash generation[24]. - The net cash flow from operating activities was -$1,229,734.74, a significant decrease from -$35,585,211.73 in the previous quarter[25]. - Total cash inflow from investment activities was $151,043,125.22, compared to $261,854,894.77 in the previous quarter, indicating a decline of approximately 42.4%[25]. - The net cash flow from investment activities was -$68,810,882.78, worsening from -$42,177,186.39 in the previous quarter[25]. - Cash inflow from financing activities totaled $20,000,000.00, while cash outflow was $30,434,991.67, resulting in a net cash flow of -$10,434,991.67[26]. - The ending cash and cash equivalents balance was $56,618,265.57, down from $78,666,223.80 in the previous quarter[26]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,645,165,559.81, a decrease of 0.76% from the end of the previous year[4]. - The company's cash and cash equivalents decreased to CNY 60,261,265.57 from CNY 140,736,190.61 at the end of 2023[16]. - The total liabilities decreased to ¥464,460,489.17 from ¥482,957,571.38 year-over-year[21]. - The company reported a total current liability of CNY 282,667,886.09, down from CNY 300,505,988.19 at the end of 2023[17]. Shareholder Information - The equity attributable to shareholders increased by 0.54% to CNY 1,223,533,561.83 compared to the end of the previous year[4]. - The total number of ordinary shareholders at the end of the reporting period was 34,263[8]. - The top ten shareholders held a total of 226,197,938 shares, accounting for 34.38% of the total shares[8]. - The total equity attributable to shareholders increased slightly to ¥1,223,533,561.83 from ¥1,216,978,966.74 in the previous year[21]. Expenses - The company recognized stock incentive expenses of CNY 14,295,625.00, which reduced net profit by CNY 11,518,012.50[4]. - The company recognized equity incentive expenses of CNY 14,295,625, resulting in a net profit reduction of CNY 11,518,012.50; excluding this impact, the net profit attributable to shareholders would be CNY 7,798,645.69[12]. - Total operating costs increased significantly to ¥79,483,781.34, up 30% from ¥61,195,825.19 in the same period last year[21]. - Research and development expenses were ¥5,495,990.24, a decrease of 16.8% from ¥6,604,724.12 in Q1 2023[21]. Other Financial Metrics - The weighted average return on equity was 0.30%, a decrease of 1.54 percentage points year-over-year[3]. - Accounts receivable rose to CNY 96,564,957.56 from CNY 84,947,031.64 at the end of 2023[16]. - Inventory decreased to CNY 93,045,354.79 from CNY 102,823,736.71 at the end of 2023[16]. - Short-term borrowings increased to CNY 70,000,000.00 from CNY 50,000,000.00 at the end of 2023[17]. - The impact of exchange rate changes on cash and cash equivalents was $684.15, contrasting with -$3,078.84 in the previous quarter[26].

证券代码：603718 证券简称：海利生物 公告编号：2024-014 上海海利生物技术股份有限公司 关于召开 2023 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海海利生物技术股份有限公司（以下简称"公司"）已于 2024 年 4 月 30 日发布公司 2023 年度报告，为便于广大投资者更全面深入地了解公司 2023 年 度经营成果、财务状况，公司计划于 2024 年 05 月 15 日 下午 13:00-14:00 举 行 2023 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2024 年 05 月 15 日 下午 13:00-14:00 会议召开时间：2024 年 05 月 15 日(星期三) 下午 13:00-14:00 会议召开地点：上海 ...

根据中国证监会上海监管局《关于对张悦采取出具警示函措施 的决定》（沪证监决〔2023〕376 号，以下简称《警示函》）查明的事 实及相关公告，上海海利生物技术股份有限公司（以下简称公司） 在 2021 年半年报中，披露财务费用少计关联方借款利息 327.40 万 元，占当期报告记载利润总额的 11.40%。2021 年三季报中，公司披 露财务费用少计关联方借款利息 635.05 万元，占当期报告记载利润 总额的 14.74%。2022 年一季报中，公司披露财务费用少计关联方借 款利息 295.50 万元，占当期报告记载利润总额的 22.70%。 定期报告是投资者关注的事项，可能对公司股价及投资者决策 产生影响，公司理应根据会计准则对当期财务数据进行客观、谨慎 地核算并披露。公司披露的财务数据披露不准确，上述行为违反了 《公开发行证券的公司信息披露编报规则第 15 号——财务报告的一 般规定》以及《上海证券交易所股票上市规则（2022 年修订）》（以 下简称《股票上市规则》）第 1.4 条、第 2.1.1 条、第 2.1.4 条等有 1 上 海 证 券 交 易 所 上证公监函〔2024〕0094 号 关于对上海 ...

上海证券交易所 纪律处分决定书 〔2024〕67 号 关于对上海海利生物技术股份有限公司及 有关责任人予以通报批评的决定 当事人： 上海海利生物技术股份有限公司，A 股证券简称：海利生物， A 股证券代码：603718； 张海明，上海海利生物技术股份有限公司时任董事长； 陈 晓，上海海利生物技术股份有限公司时任总经理； 林 群，上海海利生物技术股份有限公司时任财务总监。 -1- ──────────────────────── 一、上市公司及相关主体违规情况 根据中国证监会上海监管局《关于对上海海利生物技术股份 有限公司采取出具警示函措施的决定》（沪证监决〔2023〕374 号）、《关于对张海明采取出具警示函措施的决定》（沪证监决 〔2023〕375 号）、《关于对陈晓采取出具警示函措施的决定》（沪 证监决〔2023〕377 号）和《关于对林群采取出具警示函措施的 决定》（沪证监决〔2023〕378 号）查明的事实及相关公告，上 海海利生物技术股份有限公司（以下简称公司）在信息披露方面， 有关责任人在职责履行方面，存在以下违规行为。 一是 2023 年上半年，公司出售全资子公司山东海利生物制 品有限公司和上海 ...

上海海利生物技术股份有限公司（以下简称"公司"）全资子公司上海捷门生 物技术有限公司（以下简称"捷门生物"）于近日收到了中华人民共和国国家知识 产权局颁发的发明专利证书，具体如下： 证书号：第 6774346 号 以上发明专利的取得是捷门生物重要核心技术的体现和延伸，本次专利的获 得不会对公司近期经营产生重大影响，但有利于进一步完善公司知识产权保护体 系，发挥自主知识产权的技术优势，促进技术创新，从而提升公司核心竞争力。 证券代码：603718 证券简称：海利生物 公告编号：2024－003 上海海利生物技术股份有限公司 关于全资子公司获得发明专利的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2024 年 3 月 13 日 发明名称：一种尿液转铁蛋白检测试剂盒及其检测方法 专利号：ZL 2021 1 1323621.X 专利申请日：2021 年 11 月 10 日 专利权人：上海捷门生物技术有限公司 授权公告日：2024 年 03 月 12 日 授权公告号：CN 114047338 B 专利权期限：20 年（自 ...

证券代码：603718 证券简称：海利生物 公告编号：2024－002 上海海利生物技术股份有限公司 关于全资子公司获得发明专利的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海海利生物技术股份有限公司（以下简称"公司"）全资子公司上海捷门生 物技术有限公司（以下简称"捷门生物"）于近日收到了中华人民共和国国家知识 产权局颁发的发明专利证书，具体如下： 证书号：第 6653865 号 以上发明专利的取得是捷门生物重要核心技术的体现和延伸，本次专利的获 得不会对公司近期经营产生重大影响，但有利于进一步完善公司知识产权保护体 系，发挥自主知识产权的技术优势，促进技术创新，从而提升公司核心竞争力。 特此公告。 上海海利生物技术股份有限公司董事会 2024 年 1 月 30 日 发明名称：一种适合杂交瘤细胞贴壁生长的无血清培养基 专利号：ZL 2021 1 1533619.5 专利申请日：2021 年 12 月 15 日 专利权人：上海捷门生物技术有限公司 授权公告日：2024 年 01 月 26 日 授权公告号：CN ...

证券代码：603718 证券简称：海利生物 公告编号：2024－001 上海海利生物技术股份有限公司 关于收到上海监管局行政监管措施决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 1.2023 年上半年，你公司出售全资子公司山东海利生物制品有限公司和上海 彩音生物科技有公司 100%股权，清算、注销全资子公司上海牧海生物科技有限 公司。你公司在合并层面将部分处置收益直接计入未分配利润，未计入投资收益， 造成 2023 年半年报披露投资收益少计 4,390.56 万元，占当期报告记载利润总额 的 88.47%。此外，你公司未将上述三笔业务产生的投资收益计入非经常性损益， 造成 2023 年半年报披露扣非后净利润多计 713.17 万元，占当期报告记载扣非 后净利润的 20.92%。 2.2023 年上半年,你公司子公司杨凌金海生物技术有限公司(以下简称"杨凌 金海")向天康生物制药有限公司(以下简称"天康制药")协议转让两项技术，并 确认技术转让收入 900 万元。截至现场检查日，上述两项技术资料尚未交付天 ...

证券代码：603718 证券简称：海利生物 公告编号：2023-059 上海海利生物技术股份有限公司 2023 年第三次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 21 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 256,728,142 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 39.0223 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次临时股东大会由公司董事会召集，董事长张海明先生主持，采取现场加 网络投票方式召开并表决；会议的召集和召开符合《公司法》、《公司章程》和《股 东大会议事规则》的规定。 (一) 股东大会召开的时间：2023 年 12 月 28 日 (二) 股东大会召开的地点：上海市静安区新闸路 669 号 27 楼会议室 (三) 出席会议的普通 ...